Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


ACR: Early Damage Predicts Future Damage, Death in SLE
Second study shows poor medication adherence among U.S. Medicaid beneficiaries with SLE

TUESDAY, Oct. 29 (HealthDay News) -- For patients with systemic lupus erythematosus (SLE), early damage predicts future damage and mortality; in addition, U.S. patients with SLE have poor medication adherence, according to two studies presented at the annual meeting of the American College of Rheumatology, held from Oct. 25 to 30 in San Diego.

Ian N. Bruce, M.D., from the University of Manchester in the United Kingdom, and colleagues investigated damage accrual in early SLE using data from the Systemic Lupus International Collaborating Clinic (SLICC) Inception Cohort Study involving 1,722 patients from 31 centers in 11 countries. The researchers found that 34.8 percent of patients had one or more item of damage at baseline, increasing to 51.1 percent by six-year follow-up. For patients with initial damage, the SLICC/American College of Rheumatology damage index (SDI) was more likely to be increased at each follow-up visit. Each point increase in SDI correlated with a significantly increased risk of death (hazard ratio, 1.46).

Jinoos Yazdany, M.D., M.P.H., from the University of California in San Francisco, and colleagues examined medication adherence in SLE patients using U.S. Medicaid Analytic eXtract data from 2000 to 2006. The researchers found that the medication possession ratios (MPRs) varied from 31.1 percent for tacrolimus to 56.9 percent for hydroxychloroquine. Blacks had lower adherence than whites across all medications. Few patients had MPRs of ≥80 percent (14 percent for tacrolimus and 40 percent for mycophenolate mofetil).

"This study tells us that working with lupus patients to improve adherence is central to improving health outcomes," Yazdany said in a statement.

Abstract - Bruce
Abstract - Yazdany
More Information



Copyright © 2013 HealthDay. All rights reserved.

September 18, 2014

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

Internists Report Considerable EMR-Linked Time Loss

Doctors Promoting Transparency With Patients

FDA Approves Movantik for Opioid-Induced Constipation

Researchers ID Factor in Hospital Bacterial Resistance

Most Treatments for Acute VTE Appear Safe, Effective

CDC: Opioid-Related Deaths Quadrupled in Past Decade